UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044485
Receipt number R000050820
Scientific Title Observational study of definitive chemoradiotherapy and palliative chemotherapy using FOLFOX for esophageal squamous cell carcinoma
Date of disclosure of the study information 2021/06/09
Last modified on 2023/12/11 11:52:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational study of FOLFOX therapy for esophageal squamous cell carcinoma

Acronym

OFFER

Scientific Title

Observational study of definitive chemoradiotherapy and palliative chemotherapy using FOLFOX for esophageal squamous cell carcinoma

Scientific Title:Acronym

OFFER

Region

Japan


Condition

Condition

Esophageal squamous cell carcinoma

Classification by specialty

Gastroenterology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety of FOLFOX therapy for esophageal squamous cell carcinoma in definitive chemoradiotherapy (group A); in palliative first-line chemotherapy (group B); in salvage chemotherapy after another platinum refractory (group C)

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Group A: Complete response rate
Group B and C: response rate

Key secondary outcomes

Overall survival, progression free survival, adverse events


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Cervical or thoracic esophageal cancer, or esophagogastric junction cancer (UICC 8th)
2. Histologically proven squamous cell carcinoma
3. Intolerable to cisplatin and planned either of the treatment: definitive chemoradiotherapy for stage I-IVA disease; palliative first-line chemotherapy for stage IVB or recurrent disease; salvage chemotherapy after refractory to another platinum for stage IVB or recurrent disease
4. No previous use of oxaliplatin
5. 20 years or older
6. ECOG performance status 0, 1, 2
7. Adequate organ functions
8. Obtained informed consent

Key exclusion criteria

Patient who does not satisfy inclusion criteria

Target sample size

93


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Tsushima

Organization

Shizuoka Cancer Center

Division name

Division of Gastrointestinal Oncology

Zip code

411-8777

Address

1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka

TEL

0559895222

Email

t.tsushima@scchr.jp


Public contact

Name of contact person

1st name Kunihiro
Middle name
Last name Fushiki

Organization

Shizuoka Cancer Center

Division name

Division of Gastrointestinal Oncology

Zip code

411-8777

Address

1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka

TEL

0559895222

Homepage URL


Email

k.fushiki@scchr.jp


Sponsor or person

Institute

Shizuoka Cancer Center

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shizuoka Cancer Center

Address

1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka

Tel

0559895222

Email

tansaku_office@scchr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 12 Month 18 Day

Date of IRB

2020 Year 12 Month 25 Day

Anticipated trial start date

2021 Year 03 Month 17 Day

Last follow-up date

2023 Year 03 Month 16 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Observational study


Management information

Registered date

2021 Year 06 Month 09 Day

Last modified on

2023 Year 12 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050820


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name